Aim:Cancer-related deaths are primarily caused by lung cancer around the world.The prognosis and burden of lung cancer must be improved by identifying novel biomarkers for diagnosis and treatment.In non-small cell lun...Aim:Cancer-related deaths are primarily caused by lung cancer around the world.The prognosis and burden of lung cancer must be improved by identifying novel biomarkers for diagnosis and treatment.In non-small cell lung cancer(NSCLC),the platelet isoform of phosphofructokinase 1(PFKP)has been identified as a tumor-promoting oncogene.The current study examined the specific role that PFKP plays in NSCLC tumorigenesis,as well as the underlying mechanism.Methods:A lung cancer dataset was obtained from the TCGA in order to examine the expression of PFKP.Using the Kaplan-Meier Plotter website,we calculated the overall survival(OS)along with the recurrence-free survivals(RFS)curves with high and low levels of PFKP in lung cancer.The mechanism by which zinc finger protein 148(ZNF148)regulated PFKP/PD-L1 levels in NSCLC was investigated through chromatin immunoprecipitation(ChIP),qRT-PCR,and western blotting.In order to uncover ZNF148's function in NSCLC,subsequent functional studies included CCK-8,colony formation,and Transwell,along with glycolysis assays.Student’s T-test was conducted for data analysis with GraphPad Prism 9.0.Results:The expression of PFKP in NSCLC was increased,and it was linked to worse outcomes.This increased expression of PFKP in NSCLC was induced by ZNF148.Silencing ZNF148 remarkably dampened NSCLC cell proliferation,invasion,and glycolysis capacities.According to a mechanistic study,ZNF148 regulates the PFKP/PD-L1 axis,which promotes NSCLC tumorigenesis.Conclusion:It has been established that ZNF148-induced PFKP is key to the proliferation,invasion,and glycolysis abilities of NSCLC cells by regulating PD-L1 expression.Therefore,the ZNF148/PFKP/PD-L1 axis could be a potential biological signature and target for NSCLC diagnosis and treatment.展开更多
基金The Natural Science Foundation of Hunan Province(Nos.2021JJ40919)funded this study.
文摘Aim:Cancer-related deaths are primarily caused by lung cancer around the world.The prognosis and burden of lung cancer must be improved by identifying novel biomarkers for diagnosis and treatment.In non-small cell lung cancer(NSCLC),the platelet isoform of phosphofructokinase 1(PFKP)has been identified as a tumor-promoting oncogene.The current study examined the specific role that PFKP plays in NSCLC tumorigenesis,as well as the underlying mechanism.Methods:A lung cancer dataset was obtained from the TCGA in order to examine the expression of PFKP.Using the Kaplan-Meier Plotter website,we calculated the overall survival(OS)along with the recurrence-free survivals(RFS)curves with high and low levels of PFKP in lung cancer.The mechanism by which zinc finger protein 148(ZNF148)regulated PFKP/PD-L1 levels in NSCLC was investigated through chromatin immunoprecipitation(ChIP),qRT-PCR,and western blotting.In order to uncover ZNF148's function in NSCLC,subsequent functional studies included CCK-8,colony formation,and Transwell,along with glycolysis assays.Student’s T-test was conducted for data analysis with GraphPad Prism 9.0.Results:The expression of PFKP in NSCLC was increased,and it was linked to worse outcomes.This increased expression of PFKP in NSCLC was induced by ZNF148.Silencing ZNF148 remarkably dampened NSCLC cell proliferation,invasion,and glycolysis capacities.According to a mechanistic study,ZNF148 regulates the PFKP/PD-L1 axis,which promotes NSCLC tumorigenesis.Conclusion:It has been established that ZNF148-induced PFKP is key to the proliferation,invasion,and glycolysis abilities of NSCLC cells by regulating PD-L1 expression.Therefore,the ZNF148/PFKP/PD-L1 axis could be a potential biological signature and target for NSCLC diagnosis and treatment.
